### Contraceptive Treatment Selector

**Antiestrogens**

Ethinylestradiol

### Progestins (Combined Oral Contraceptive, COC)

- **Desogestrel**
  - 1% h 1% h 1% h 1% h 1% h 1% h 1% h 1% h 1% h 1% h
  - 5% h 5% h 5% h 5% h 5% h 5% h 5% h 5% h 5% h 5% h
  - Increased conversion to the active metabolite, etonogestrel.
- **Drospirenone**
  - 1% h 1% h 1% h 1% h 1% h 1% h 1% h 1% h 1% h 1% h
  - Caution is recommended and additional contraceptive measures should be used.
- **Gestodene**
  - 1% h 1% h 1% h 1% h 1% h 1% h 1% h 1% h 1% h 1% h
  - Caution is recommended and additional contraceptive measures should be used.
- **Levonorgestrel**
  - 1% h 1% h 1% h 1% h 1% h 1% h 1% h 1% h 1% h 1% h
  - Potential interaction which may require a dose adjustment or close monitoring.
- **Norethisterone (Norinyl)**
  - 1% h 1% h 1% h 1% h 1% h 1% h 1% h 1% h 1% h 1% h
  - These drugs should not be coadministered.
- **Norgestrel**
  - 1% h 1% h 1% h 1% h 1% h 1% h 1% h 1% h 1% h 1% h
  - Potential interaction predicted to be of weak intensity.
- **Norethisterone (Noristerone)**
  - 1% h 1% h 1% h 1% h 1% h 1% h 1% h 1% h 1% h 1% h
  - Potential interaction may require a dose adjustment or close monitoring.

### Progestins (Progestin only pill, POP)

- **Desogestrel**
  - 1% h 1% h 1% h 1% h 1% h 1% h 1% h 1% h 1% h 1% h
  - Caution is recommended and additional contraceptive measures should be used.
- **Drospirenone**
  - 1% h 1% h 1% h 1% h 1% h 1% h 1% h 1% h 1% h 1% h
  - Caution is recommended and additional contraceptive measures should be used.
- **Levonorgestrel**
  - 1% h 1% h 1% h 1% h 1% h 1% h 1% h 1% h 1% h 1% h
  - Potential interaction which may require a dose adjustment or close monitoring.
- **Norgestrel**
  - 1% h 1% h 1% h 1% h 1% h 1% h 1% h 1% h 1% h 1% h
  - Potential interaction which may require a dose adjustment or close monitoring.

### Estrogens

Ethinylestradiol

<table>
<thead>
<tr>
<th>Treatment</th>
<th>ATV/ r</th>
<th>ATV/ c</th>
<th>DRV/ c</th>
<th>DRV/ r</th>
<th>LPV/ r</th>
<th>DOR</th>
<th>EFV</th>
<th>ETV</th>
<th>NVP</th>
<th>RPV (oral)</th>
<th>FTR</th>
<th>MVC</th>
<th>BIC/ EFVAT</th>
<th>CAB (oral)</th>
<th>CAB (RPV)</th>
<th>DTG</th>
<th>EVG/ EFVAT</th>
<th>EVG/ c/ F7TDF</th>
<th>FAL</th>
<th>TAF/ TDF</th>
<th>FTC/ TDF</th>
<th>TDF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antibiotics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antifungals</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antihypertensives</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antimicrobials</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antimetabolites</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antirespiratory</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antituberculars</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antivirals</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Interactions with Abacavir (ABC), Lamivudine (3TC) or Zidovudine (ZDV)

ABC: No clinically relevant interactions expected.

3TC: No clinically relevant interactions expected.

ZDV: No clinically relevant interactions expected.

### Notes

- **Product labels for ATV/c advise coadministration with hormonal contraceptives should be avoided and an alternate (non-hormonal) reliable method of contraception is recommended.**
- **Unboosted ATV increased ethinylestradiol AUC by 48%. Use no more than 30 µg of ethinylestradiol with unboosted ATV, and at least 35 µg of ethinylestradiol with ATV/c.**
- **Alternative or additional contraceptive measures are recommended.**
- **No effect on the progestin is expected, but ethinylestradiol is expected to increase.**
- **Increased conversion to the active metabolite, etonogestrel.**
- **When used in a COC the estrogen component is reduced. In the absence of clinical contraceptive efficacy data, use with caution and with additional contraceptive measures.**
- **A reliable barrier contraceptive method must be used in addition to oral contraception.**
- **When used in a COC, the estrogen component is reduced to a limited extent. The European product label states a hormonal contraceptive should contain at least 30 µg ethinylestradiol.**
- **Clinical monitoring is recommended due to the potential for hyperkaemia.**